Similar results were reported on in vitro and in vivo models of Alzheimer’s dementia where etanercept treatment reduced the concentration of pro-inflammatory cytokines and, subsequently, neuron injury by activating the c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF-κB) pathways thus exerting neuroprotectors effects. Here, MAPK8 is linked to Alzheimer disease.